Moderna, Inc. MRNA shares are trading lower Monday alongside other vaccine stocks amid a selloff after the sector gained amid rising cases. Weakness comes after Pfizer said it expects a 24% vaccination rate this year.
What Else: Moderna stock has gained nearly 10% in past few weeks on rising COVID cases in the US. Recently, shares of Moderna were boosted by news that the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending authorization of the company's updated COVID-19 vaccine in the EU.
However, Moderna stock was down nearly 9% Monday, marking a selloff from the recent high.
Related Link: Trump Vs. Biden, Cannabis Legalization Could Play A Bigger Role Than Their Ages
MRNA Price Action: Shares of MRNA were down 8.22% at $105.17 at the time of publication, according to Benzinga Pro.
Image by fernando zhiminaicela from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
